Sho Takahata

Summary

Affiliation: Meiji Seika Kaisha
Country: Japan

Publications

  1. pmc Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Yokohama, Japan
    Antimicrob Agents Chemother 51:1589-95. 2007
  2. ncbi request reprint In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans
    Sho Takahata
    Pharmaceutical Research Department, Meiji Seika Kaisha Ltd, Kohoku Ku, Yokohama, Japan
    Med Mycol 43:227-33. 2005
  3. ncbi request reprint Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    J Antibiot (Tokyo) 60:123-8. 2007
  4. pmc Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 52:1880-3. 2008
  5. pmc Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 50:3638-45. 2006
  6. pmc AG205, a novel agent directed against FabK of Streptococcus pneumoniae
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 50:2869-71. 2006
  7. doi request reprint Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama, Japan
    Int J Antimicrob Agents 35:333-7. 2010
  8. ncbi request reprint Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK
    Hideo Kitagawa
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    J Med Chem 50:4710-20. 2007
  9. ncbi request reprint Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK
    Tomohiro Ozawa
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Bioorg Med Chem 15:7325-36. 2007
  10. pmc Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor
    Jun Saito
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kohoku Ku, Yokohama 222 8567, Japan
    Protein Sci 17:691-9. 2008

Detail Information

Publications14

  1. pmc Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Yokohama, Japan
    Antimicrob Agents Chemother 51:1589-95. 2007
    ..In conclusion, horizontal transfer of the ftsI gene in H. influenzae can occur in an intraspecies and an interspecies manner...
  2. ncbi request reprint In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans
    Sho Takahata
    Pharmaceutical Research Department, Meiji Seika Kaisha Ltd, Kohoku Ku, Yokohama, Japan
    Med Mycol 43:227-33. 2005
    ..albicans, as well as for the treatment of pulmonary aspergillosis...
  3. ncbi request reprint Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    J Antibiot (Tokyo) 60:123-8. 2007
    ..aureus. In conclusion, we have identified a novel chemical series, 4-pyridone derivatives, as specific inhibitors of FabI with potent antibacterial activity against S. aureus...
  4. pmc Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 52:1880-3. 2008
    ..Compared to the penicillins and the carbapenem, the cephalosporins showed a wide selection window for the genetic transfer...
  5. pmc Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 50:3638-45. 2006
    ..Therefore, three mutations (G545S, I312M, and V316T) in mosaic PBP2 were identified as the amino acid substitutions responsible for reduced susceptibility to cefixime in N. gonorrhoeae...
  6. pmc AG205, a novel agent directed against FabK of Streptococcus pneumoniae
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 50:2869-71. 2006
    ..pneumoniae through the specific inhibition of FabK...
  7. doi request reprint Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli
    Sho Takahata
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama, Japan
    Int J Antimicrob Agents 35:333-7. 2010
    ..In conclusion, novel amino acid substitutions in MurA or the loss of function of transporters were identified as mechanisms of fosfomycin resistance in clinical isolates of E. coli...
  8. ncbi request reprint Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK
    Hideo Kitagawa
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    J Med Chem 50:4710-20. 2007
    ..Moreover, this compound showed no significant cytotoxicity (IC50 > 69 microM). These results support compound 6 as a novel agent for the treatment of bacterial infections...
  9. ncbi request reprint Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK
    Tomohiro Ozawa
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Bioorg Med Chem 15:7325-36. 2007
    ..Based on structure-activity relationship (SAR) studies of our screening hits, we have developed novel phenylimidazole derivatives as potent FabK inhibitors...
  10. pmc Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor
    Jun Saito
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kohoku Ku, Yokohama 222 8567, Japan
    Protein Sci 17:691-9. 2008
    ..We propose that the primary basis of the inhibitory activity is competition with NADH for binding to FabK, which is the first step of the two-step ping-pong catalytic mechanism...
  11. ncbi request reprint Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK
    Hideo Kitagawa
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Yokohama, Japan
    Bioorg Med Chem Lett 17:4982-6. 2007
    ..Through SAR studies of our initial hit compound 2-(1H-benz[d]imidazol-2-ylthio)-N-(6-methoxycarbonylbenzo[d]thiazol-2-yl)acetamide, a series of novel phenylimidazole derivatives were discovered as potent FabK inhibitors...
  12. ncbi request reprint 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI
    Hideo Kitagawa
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Bioorg Med Chem 15:1106-16. 2007
    ..Structure optimization studies yielded 4-pyridone derivatives 7n having strong FabI-inhibitory and antibacterial activities against Staphylococcus aureus. There have been no reports concerning 4-pyridone derivatives as FabI inhibitor...
  13. doi request reprint Correlation of the antimicrobial activity of ME1036 with its binding affinities to the penicillin-binding proteins from Streptococcus pneumoniae strains
    Yoko Hirai
    Pharmaceutical Research Center, Meiji Seika Pharma, Kanagawa, Japan
    J Antibiot (Tokyo) 64:741-6. 2011
    ..pneumoniae (gPISP) strains and genotypic penicillin-resistant S. pneumoniae (gPRSP) strains that contain more than one mutation in their PBPs, owing to its strong affinity for those PBPs...
  14. pmc Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus
    Jun Nagura
    Pharmaceutical Research Department, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Antimicrob Agents Chemother 49:3526-8. 2005
    ..Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis...